The deal will expand PharmaLex's offering to the life sciences sector
Piper Alderman has acted for PharmaLex on its merger agreement with Cpharm, a specialist consultancy providing pharmacovigilance, medical information and patient program services in Australia and New Zealand.
PharmaLex provides specialised services for the pharma, biotech, and medtech industries. Cpharm is based in Hunter Valley, NSW. The company provides collaborative pharmaceutical services to clients from start-ups to the top ten multinational healthcare companies. PharmaLex’s merger deal with Cpharm is expected to help expand PhamarLex’s service offering to the life sciences sector, growing its specialty services in Australia and globally.
During its transaction with Cpharm, the global PharmaLex Group has also merged with AmerisourceBergen Corporation. AmerisourceBergen is a global healthcare company with a foundation in pharmaceutical distribution and solutions for manufacturers, pharmacies and providers.
Managing director of PharmaLex’s Australian division Grant Bennett said, “Having worked with the Cpharm team for a number of years as specialist subcontractors, we are pleased to combine the businesses to provide a more comprehensive range of services to our clients.”
Piper Alderman partner Lis Boyce led the team that advised on the deal. Senior associate Bahar Agar supported the team. Lawyers Francesca Lombardo and Samiha Asim assisted PharmaLex with undertaking legal due diligence on Cpharm’s business operations and prepared the transaction documents to acquire shares in Cpharm.
Piper Alderman’s employment team, led by Tim Capelin with support from associate Emily Setter, was involved in preparing employment agreements for key employees of the Cpharm business. Property partner Marcus Andrews supported the deal in relation to new lease documentation.
“We were also glad to continue our collaboration with Piper Alderman as our Australian legal advisers and draw on their deep experience of deals in the life sciences sector,” Bennett said.
Boyce also commented on the deal, “Having supported the local leadership team of PharmaLex through their own merger with PharmaLex GmbH in 2021, we were delighted to work with the global team of PharmaLex and AmerisourceBergen on this strategic transaction.”
